ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

½¼Òº£ÍŶӷ¢Ã÷¿ÉÒÔÒÖÖÆ»ù¿×¿ÏÑÅÈȲ¡¶¾ÔçÆÚ¸´ÖƵÄÌØÒìÐÔÄÉÃ׿¹Ìå

¸å¼þȪԴ£º£º¹«¹²ÎÀÉúѧԺ ±à¼­£º£ºÌ¸Ï£¡¢¡¢¡¢Íõ¶¬Ã· ÉóºË£º£ºÖª×ã ÔĶÁÁ¿£º£º

ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±ÒÁ²©Ñô£©»ù¿×¿ÏÑÅÈÈ£¨CHIKF£©ÊÇÓÉ»ù¿×¿ÏÑŲ¡¶¾£¨CHIKV£©ÒýÆð£¬£¬£¬¾­ÒÁÎÃÈö²¥£¬£¬£¬ÒÔ·¢ÈÈ¡¢¡¢¡¢Æ¤Õî¼°ÊàŦÌÛʹΪÖ÷ÒªÌØÕ÷µÄ¼±ÐÔѬȾ²¡¡£¡£CHIKVͨ³£ÔÚ·ÇÈËÀàÁ鳤ÀදÎï¡¢¡¢¡¢²¸È鶯ÎïËÞÖ÷ºÍÎóæÖ®¼äÒÔÇúÏßʽѭ»·Èö²¥¡£¡£1952ÄêÊ×´ÎÔÚ̹ɣÄáÑÇ֤ʵÁË»ù¿×¿ÏÑÅÈÈÊ¢ÐУ¬£¬£¬1956ÄêÊèÉ¢µ½²¡¶¾¡£¡£2005£­2007Äê±¾²¡ÔÚÓ¡¶ÈÑóµºÓì¡¢¡¢¡¢Ó¡¶ÈºÍ¶«ÄÏÑǵØÇøÆÕ±éÊ¢ÐУ¬£¬£¬µ¼ÖÂÊý°ÙÍòÈË»¼²¡¡£¡£ÏÖÔÚ£¬£¬£¬ÔÚÑÇÖÞ¡¢¡¢¡¢·ÇÖÞ¡¢¡¢¡¢Å·ÖÞÒÔ¼°ÃÀÖ޵Ľü60¸ö¹ú¼ÒÒѾ­È·ÈÏÓлù¿×¿ÏÑŲ¡Àý±¬·¢¡£¡£

¹ØÓÚCHIKVµÄ·ÀÖΣ¬£¬£¬ÏÖÔÚûÓпÉÒÔʹÓõÄÒßÃçÉÏÊУ¬£¬£¬Ò²Ã»Óо­ÓÉÅú×¼µÄ¿¹²¡¶¾ÖÎÁÆÒªÁ죬£¬£¬Í¨³£ÊÇʹÓ÷ÇçÞÌåÀ࿹Ñ×Ò©»òÀà¹Ì´¼£¬£¬£¬ÎÔ´²ÐÝÏ¢£¬£¬£¬ÒÔ¼°Ôö²¹Ë®·Ö¡£¡£ÖØÁ´¿¹ÌåµÄÖØÁ´µÄ¿É±äÇø³ÆÎªVHH£¬£¬£¬Í¨¹ýÌåÍâÖØ×é±í´ïÖÆ±¸µÄVHH·Ö×ÓÖÊÁ¿½ö½öΪ15kDa£¬£¬£¬ÊǹŰ忹ÌåµÄÊ®·ÖÖ®Ò»×óÓÒ£¬£¬£¬ÊÇ¿¹Ô­Á¬ÏµÆ¬¶ÏµÄ¶þ·ÖÖ®Ò»×óÓÒ£¬£¬£¬Òò´Ë±»³ÆÎªÄÉÃ׿¹Ì壨nanobody, Nb£©¡£¡£Óë¹Å°å¿¹ÌåÏà±È£¬£¬£¬ÄÉÃ׿¹Ìå¿ÉÒÔʶÍâ¹Å°å¿¹Ìå²»¿Éʶ±ðµÄλµãÓÉÓÚÄÉÃ׿¹Ìå½ÏСµÄ³ß´çÒÔ¼°ÌØÊâµÄCDR3½á¹¹£¬£¬£¬Ôö½øÁËÆäÓë¹Å°å¿¹ÌåËù²»¿ÉµÖ´ïµÄбíλµÄÏ໥×÷Ó㬣¬£¬Òò´ËÄÉÃ׿¹Ìå¾ß±¸Á¬ÏµºÍÖк͹Ű忹ÌåÄÑÒÔÖÀÖеİеãµÄÄÜÁ¦£¬£¬£¬ÊÊÓÃÓÚ²¡¶¾µÄ°ÐÏòÖÎÁÆ¡£¡£

B83A9DF13F4900FE46C43212BA2_E3EC9B16_9B8F

ͼ1 ʵÑé·½°¸


¿ËÈÕ£¬£¬£¬ngµç×ÓÓÎÏ·¹«¹²ÎÀÉúѧԺ½¼Òº£½ÌÊÚ¡¢¡¢¡¢³ÂÔóÁ¼½ÌÊں͵ÚÒ»×÷ÕßµËÇ¿£¨ÔÚ¶Á²©Ê¿Éú£©µÈÔÚ¿¹²¡¶¾Ñо¿ÁìÓòÖ÷ҪѧÊõÆÚ¿¯Antiviral Research£¨IF=10.103£©ÉϽÒÏþÁËÌâΪ¡°Inhibition of Chikungunya virus early replication by intracellular nanoantibodies targeting nsP2 Epitope Rich Region¡±µÄÑо¿ÂÛÎÄ¡£¡£¸ÃÏîÑо¿ÓÉngµç×ÓÓÎÏ·¹«¹²ÎÀÉúѧԺ½¼Òº£½ÌÊÚÍŶÓÁìÏΣ¬£¬£¬ÁªºÏÖÐÍâÍŶÓ£¬£¬£¬ÔڿƼ¼²¿ÖصãÑз¢ÍýÏëºÍ¹ã¶«Ê¡¶Ô½Ó¹ú¼ÒÖØ´óÏîĿ֧³ÖÏ£¬£¬£¬´ÓÑòÍÕ×ÔÈ»ÊɾúÌå¿âÖÐɸѡ³öÁ˶à¸öÕë¶ÔCHIKV²¡¶¾nsP2¿¹Ô­µÄÌØÒìÐÔÄÉÃ׿¹Ìå¡£¡£Ñо¿·¢Ã÷ÄÉÃ׿¹ÌåÄܹ»ÒÖÖÆ²¡¶¾ÔçÆÚ¸´ÖÆ¡£¡£¿£¿£¿¹ÌåµÄ»ñµÃ£¬£¬£¬Îª½øÒ»²½Ñо¿CHIKV nsP2¹¦Ð§£¬£¬£¬¿ª·¢ÖÎÁÆÒ©ÎïµÈµÓÚ¨ÁË»ù´¡¡£¡£

ngµç×ÓÓÎÏ·¹«¹²ÎÀÉúѧԺ²©Ê¿ÉúµËǿΪÂÛÎĵÚÒ»×÷Õߣ¬£¬£¬Â½¼Òº£º£ºÍ³ÂÔóÁ¼½ÌÊÚΪÂÛÎÄͨѶ×÷Õߣ¬£¬£¬ngµç×ÓÓÎÏ·¹«¹²ÎÀÉúѧԺΪ¸ÃÊÂÇéµÄµÚÒ»Íê³Éµ¥Î»¡£¡£ÉÏÊöÑо¿»ñµÃÁ˹ú¼ÒÖØµãÑз¢ÍýÏëÏîÄ¿(2018YFE0208000)¡¢¡¢¡¢¹ã¶«Ê¡ÖصãÁìÓòÑз¢ÍýÏëÏîÄ¿(2018B020241002)¡¢¡¢¡¢ÉîÛÚÊпƼ¼ÍýÏë (JSGG20220606142207017)¡¢¡¢¡¢¹ã¶«Ê¡Ò©Æ·¼àÊÓÖÎÀí¾Ö¿Æ¼¼Á¢ÒìÏîÄ¿£¨2022ZDZ12£©ºÍÖÐÑëÖ¸µ¼µØ·½¿Æ¼¼¿ªÕ¹×ʽð×ÔÓÉ̽Ë÷Àà»ù´¡Ñо¿ÏîÄ¿£¨2021Szvup171£©¡£¡£

ÂÛÎÄÁ´½Ó£º£ºhttps://doi.org/10.1016/j.antiviral.2022.105446

¡¾ÍøÕ¾µØÍ¼¡¿